Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia

Gergely Toldi, Edina Bíró, Balázs Szalay, Balázs Stenczer, A. Molvarec, J. Rigó, B. Vásárhelyi, G. Bekő

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy. Methods: We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy. Results: Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30-4.71) ng/mL vs. 2.02 (1.81-2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97-18.12) pg/mL vs. 1.41 (1.00-2.70) pg/mL, p=0.0001 and 6.60 (3.55-15.40) mg/L vs. 3.90 (2.10-7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels. Conclusions: suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.

Original languageEnglish
Pages (from-to)1873-1876
Number of pages4
JournalClinical Chemistry and Laboratory Medicine
Volume49
Issue number11
DOIs
Publication statusPublished - Nov 1 2011

Fingerprint

Urokinase Plasminogen Activator Receptors
Pre-Eclampsia
Pregnancy
C-Reactive Protein
Interleukin-6
Plasmas
Inflammation
Mothers
Immune Tolerance
Monitoring
Third Pregnancy Trimester
Biomarkers
Linear regression
ROC Curve
Linear Models
Regression Analysis
Association reactions

Keywords

  • High sensitivity C-reactive protein
  • IL-6
  • Preeclampsia
  • Pregnancy
  • SuPAR

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia. / Toldi, Gergely; Bíró, Edina; Szalay, Balázs; Stenczer, Balázs; Molvarec, A.; Rigó, J.; Vásárhelyi, B.; Bekő, G.

In: Clinical Chemistry and Laboratory Medicine, Vol. 49, No. 11, 01.11.2011, p. 1873-1876.

Research output: Contribution to journalArticle

@article{ecf87a14dd044b23aa6a06176052b931,
title = "Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia",
abstract = "Background: Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy. Methods: We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy. Results: Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30-4.71) ng/mL vs. 2.02 (1.81-2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97-18.12) pg/mL vs. 1.41 (1.00-2.70) pg/mL, p=0.0001 and 6.60 (3.55-15.40) mg/L vs. 3.90 (2.10-7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels. Conclusions: suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.",
keywords = "High sensitivity C-reactive protein, IL-6, Preeclampsia, Pregnancy, SuPAR",
author = "Gergely Toldi and Edina B{\'i}r{\'o} and Bal{\'a}zs Szalay and Bal{\'a}zs Stenczer and A. Molvarec and J. Rig{\'o} and B. V{\'a}s{\'a}rhelyi and G. Bekő",
year = "2011",
month = "11",
day = "1",
doi = "10.1515/CCLM.2011.656",
language = "English",
volume = "49",
pages = "1873--1876",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "11",

}

TY - JOUR

T1 - Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia

AU - Toldi, Gergely

AU - Bíró, Edina

AU - Szalay, Balázs

AU - Stenczer, Balázs

AU - Molvarec, A.

AU - Rigó, J.

AU - Vásárhelyi, B.

AU - Bekő, G.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background: Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy. Methods: We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy. Results: Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30-4.71) ng/mL vs. 2.02 (1.81-2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97-18.12) pg/mL vs. 1.41 (1.00-2.70) pg/mL, p=0.0001 and 6.60 (3.55-15.40) mg/L vs. 3.90 (2.10-7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels. Conclusions: suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.

AB - Background: Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy. Methods: We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy. Results: Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30-4.71) ng/mL vs. 2.02 (1.81-2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97-18.12) pg/mL vs. 1.41 (1.00-2.70) pg/mL, p=0.0001 and 6.60 (3.55-15.40) mg/L vs. 3.90 (2.10-7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels. Conclusions: suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.

KW - High sensitivity C-reactive protein

KW - IL-6

KW - Preeclampsia

KW - Pregnancy

KW - SuPAR

UR - http://www.scopus.com/inward/record.url?scp=80755130081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755130081&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2011.656

DO - 10.1515/CCLM.2011.656

M3 - Article

C2 - 21722073

AN - SCOPUS:80755130081

VL - 49

SP - 1873

EP - 1876

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 11

ER -